Clinical Trial Update: A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma [Phase 3]

View source ↗

Summary

Phase III trial evaluating elotuzumab in VRD induction/consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)

Snippet

Sponsor: University of Heidelberg Medical Center | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED